
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
The European Commission (EC) has granted conditional marketing approval to Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab) for treatment of adults with relapsed and refractory (R/R) multiple myeloma (MM), Regeneron announced on April 28, 2025 (1). …